There are roughly 40,000 people in federal and state prisons serving sentences for cannabis-related offenses. When the Trump administration moves — as early as Wednesday, according to an administration official who spoke to Axios — to reclassify marijuana from a Schedule I to a Schedule III controlled substance, not one of them will be released. Not one sentence will be reviewed. Not one conviction will be reconsidered. The rescheduling changes what researchers can study. It does not change who goes home.
That gap — between what this announcement does and what it is being sold as — is the story.
The rescheduling process itself has been grinding forward since Trump signed an executive order directing it last year. The Drug Enforcement Administration process for reclassifying a controlled substance is deliberately slow, designed to move through public comment periods, agency review, and interagency coordination. The administration has known for months this was coming. The decision to announce it now, in the middle of a news cycle dominated by the Iran war, energy prices, and domestic unrest, is not an accident of timing. It is the point of timing.
Schedule I drugs are classified as having no accepted medical use and a high potential for abuse. Schedule III drugs — which include ketamine and anabolic steroids — are recognized as having medical applications and carry lower regulatory barriers for research. Moving marijuana to Schedule III does not legalize it federally, does not expunge prior convictions, and does not affect state-level prohibition.
The administration official's framing to Axios was careful: the move would make it easier to study marijuana's medicinal applications and could shore up support from influencers who back cannabis research. That last phrase is worth sitting with. Not patients. Not the communities most harmed by drug enforcement. Influencers. The political calculus here is visible from a distance: cannabis rescheduling polls well across party lines, costs the administration nothing materially, and generates a news cycle that looks like reform without requiring any of its difficult work.
What that difficult work would actually look like has a name: clemency. The Biden administration granted pardons for simple federal marijuana possession in 2022, though critics — including advocacy groups like the ACLU — noted at the time that the pardons applied to a relatively small universe of federal cases and did nothing for the far larger number of people incarcerated under state law. The Trump administration has shown no interest in extending or expanding that approach. Rescheduling and clemency are entirely separate levers. Moving marijuana to Schedule III does not pull the second one.
The systemic pattern here is worth naming directly. For decades, drug scheduling has been used as a political instrument — not primarily as a scientific or public health tool. The Nixon administration's own advisors have since acknowledged that the original Schedule I classification of marijuana was designed to criminalize Black communities and the antiwar left, not to reflect any genuine pharmacological assessment. The DEA's own administrative law judge recommended rescheduling marijuana in 1988. The agency overruled him. The science did not change. The politics did not align.
What has changed, finally, is the politics — and that is precisely why this administration is moving now. Thirty-eight states have legalized marijuana in some form. A legal cannabis and hemp industry worth tens of billions now exists in direct regulatory conflict with federal Schedule I status. Major cannabis companies have been lobbying for rescheduling for years, not because they care about the people still imprisoned, but because Schedule I classification prevents them from accessing banking services, taking standard business tax deductions, and operating with the legitimacy of a federally recognized industry. The business community wanted this. They are getting it.
The accountability question this story demands is not whether rescheduling is good policy in the abstract — it is. Reducing DEA barriers to medical research is a legitimate public health benefit. The question is what this administration chose not to do at the same moment. Rescheduling requires no congressional vote. Neither does expanding clemency review. Neither does directing the Justice Department to deprioritize federal cannabis prosecutions in states where marijuana is legal. These are executive actions available to the same administration that is moving on Schedule III. It is choosing not to take them.
The communities bearing that cost are not abstractions. Black Americans are arrested for marijuana possession at 3.7 times the rate of white Americans, according to ACLU data, despite comparable usage rates across racial groups. That disparity runs through every level of the system: arrest, prosecution, sentencing, incarceration. A policy that loosens restrictions on cannabis research while leaving that enforcement architecture untouched is not drug reform. It is drug industry reform — a different thing, serving different people.
Policy experts and criminal justice advocates have noted for years that rescheduling, while necessary, was never sufficient. The argument was always that the scheduling system itself — a product of political decisions dressed up as pharmacological science — needed to be accompanied by retroactive relief for those caught in its machinery. That argument has not changed. What has changed is that the business case for rescheduling has grown large enough that even an administration with no stated interest in criminal justice reform finds it convenient.
There is also the question of what this announcement is displacing. Democracy watchdogs have documented a pattern of this administration using policy announcements that generate positive coverage to create breathing room on weeks when accountability coverage is running hard. The Iran war, the $12 billion in unauthorized war spending, the ongoing legal battles over executive power — these are the stories that a marijuana announcement lands alongside. That context is not conspiratorial. It is editorial judgment about what gets covered and what gets buried in the same news cycle.
The rescheduling will likely happen. It will be covered as a win — and in narrow terms, it is. But every account of this announcement that does not name what it omits is doing the administration's communications work for it. The 40,000 people serving time for cannabis did not become less relevant because the DEA updated a classification. They became the proof of what this reform was always willing to leave behind.
